1	Hidden changes to prespecified primary outcomes of clinical trials completed between 2009 and
2	2017 in German University Medical Centres: A meta-research study
3	
4	
5	Martin R. Holst (MRH) * <sup>T1,2</sup> <u>https://orcid.org/0000-0002-8135-6265</u> <u>martin.holst@bih-charite.de</u>
6	Martin Haslberger (MH) *1 <u>https://orcid.org/0000-0002-8067-2856</u> martin.haslberger@bih-charite.de
7	Samruddhi Yerunkar (SY) <sup>1</sup> <u>https://orcid.org/0000-0002-0748-383X</u> samruddhi.yerunkar@charite.de
8	Daniel Strech (DS) <sup>1</sup> <u>https://orcid.org/0000-0002-9153-079X</u> <u>daniel.strech@bih-charite.de</u>
9	Lars G. Hemkens (LGH) <sup>3-6</sup> <u>https://orcid.org/0000-0002-3444-1432</u> <u>lars.hemkens@usb.ch</u>
10	Benjamin G. Carlisle (BGC) <sup>1</sup> <u>https://orcid.org/0000-0001-8975-0649</u> <u>benjamin.carlisle@bih-charite.de</u>
11	
12	
13	<sup>T</sup> Corresponding author (email <u>martin.holst@bih-charite.de</u> ; phone: +49 30 450 543 669; Twitter:
14	@MartinHolst9)
15	* These authors contributed equally
16	
17	
18	<sup>1</sup> Berlin Institute of Health at Charité – Universitätsmedizin Berlin, QUEST Center for Responsible
19	Research, Charitéplatz 1, 10117 Berlin, Germany
20	<sup>2</sup> Medizinische Hochschule Hannover, Institute for Ethics, History and Philosophy of Medicine, Carl-
21	Neuberg-Str. 1, 30625 Hannover
22	<sup>3</sup> Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
23	<sup>4</sup> Berlin Institute of Health at Charité – Universitätsmedizin Berlin, QUEST Center for Responsible
24	Research, Meta-Research Innovation Center Berlin, Charitéplatz 1, 10117 Berlin, Germany
25	<sup>5</sup> Meta-Research Innovation Center at Stanford, Stanford University, Stanford, California
26	<sup>6</sup> Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University

27 Hospital Basel and University of Basel, Basel, Switzerland

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 28 **Previous versions:** Preliminary data of this study were presented at the 9<sup>th</sup> International Conference
- 29 on Peer Review and Scientific Publication, Chicago, 9 September 2022.
- 30 Code and data availability: Analysis code and original datasets are available on Github
- 31 (https://github.com/Martin-R-H/HiddenOutcomeChanges). The final dataset has been posted to our
- 32 OSF page (<u>https://osf.io/e2uct/</u>).

33 **Ethics approval:** Not applicable.

- 34 Transparency statement: The lead authors affirm that the manuscript is an honest, accurate, and
- 35 transparent account of the study being reported. No important aspects of the study have been
- 36 omitted. Any discrepancies from the study as registered (https://osf.io/t3qva) are explained in a
- 37 registration amendment (https://osf.io/qtd2b). Most importantly, due to the complexity of the
- 38 project and the large amount of manual screening involved, we decided to split the preregistered
- 39 project in two standalone projects (outcome discrepancies and spin), which we report in separate
- 40 publications. The authors declare no conflicts of interest.
- 41 Role of the funding source: This work was funded under a grant from the Federal Ministry of
- 42 Education and Research of Germany (Bundesministerium fuer Bildung und Forschung BMBF)
- 43 [01PW18012]. The funder was not involved in the study design, data collection, analysis, or
- 44 interpretation, writing of the manuscript, or the decision to submit for publication.
- 45 **Patient and Public Involvement statement:** No patients were involved in this study. There was no
- 46 public involvement for this study.
- 47 **Dissemination to participants and related patient and public communities:** Not applicable.

49	Abstract
50	
51	Objectives: To assess how often clinical trials exhibit primary outcome discrepancies within registry
52	records that would not be caught by comparing results publications to the latest registry entry, but
53	would require analysing the registration history.
54	Design: Meta-research study.
55	Setting: All 1746 randomised clinical trials with published results, registered in ClinicalTrials.gov or
56	Deutsches Register Klinischer Studien (DRKS), completed at German University Medical Centres
57	between 2009 and 2017. We analysed registry entries for all trials and publications for a random
58	sample of 292 trials.
59	Participants: Not applicable.
60	Interventions: Not applicable.
61	Main outcome measures: [1] Primary outcome discrepancies between registry entries at key study
62	milestones and [2] the first results publication. [3] 'Hidden' discrepancies, i.e., only reported in the
63	registry before the last entry, meaning they would only be detected by assessing the full registry
64	change history. We considered discrepancies major if primary outcomes were newly added, dropped,
65	or changed to or from secondary outcomes. [4] Proportion of publications transparently reporting
66	discrepancies. [5] Characteristics associated with 'open' and 'hidden' discrepancies.
67	Results: Of all 1746 trials, 23% (n=393) had primary outcome discrepancies between trial start and
68	latest registry entry, with 8% (n=142) being major. Primary outcomes in publications were different
69	from the latest registry entry in 41% of trials (120 of the 292 sampled trials; 95% CI [35%, 47%]), with
70	major discrepancies in 18% (54 of 292; 95% CI [14%, 23%]). 'Hidden' discrepancies were observed in
71	14% of trials (41/292; 95% CI [10%, 19%]). Only 1% of discrepancies were reported in the publications
72	(2/161, 95% CI [0%, 4%]). Trials were more likely to have a within-registry discrepancy if they had an
73	earlier registration year (OR 0.74; 95% CI [0.69, 0.80]), were registered on ClinicalTrials.gov (OR 0.41;
74	95% CI [0.23, 0.70]), or had been industry-sponsored (OR 0.29; 95% CI [0.21, 0.41]).
75	Conclusions: Changes to primary trial outcomes are common, often have major relevance, are rarely
76	transparently reported and typically not detectable with an inspection of the latest registry entry.
77	Authors need to be more transparent and registry entries of published trials need to require more in-
78	depth analysis to reveal potentially misleading reporting practices.
79	Protocol registration: Open Science Framework ( <u>https://osf.io/t3qva</u> ; amendment in
80	https://osf.io/qtd2b).
81	
82	Keywords: Clinical Trials, Registration, Reporting, Transparency

### 83 Introduction 84 85 Clinical trial registries are critical tools to enhance the transparency and trustworthiness of clinical 86 trial evidence by openly reporting key study parameters in a rapidly accessible manner (1). They 87 make it possible to detect selective reporting biases that pose a major threat to trustworthiness. One 88 of the most critical possible deviations from an original protocol and analysis plan is a change to 89 prespecified outcomes. Consequently, outcomes and their pre-specification are among the most 90 critical reporting items of clinical trials, with the CONSORT statement asking to describe 'completely 91 defined pre-specified primary and secondary outcome measures, including how and when they were 92 assessed' as well as 'any changes to trial outcomes after the trial commenced, with reasons' (2). If 93 readers do not know if the outcomes were changed, they cannot assess the risk of bias due to 'cherry 94 picking' of results or implications of multiple testing (3). 95 Many clinical trial registries, such as ClinicalTrials.gov, allow entries to be updated after initial 96 registration. While updating a registry entry is generally useful, as it is not unusual for parts of a trial 97 protocol to change and desirable for an entry to reflect the most current information, it constitutes 98 another possible source of reporting bias if entries are not properly maintained and larger changes 99 go unreported. While a number of ethical and reporting guidance documents recommend 100 prospective trial registration (2,4,5) and some recommend the transparent reporting of protocol 101 changes (2,4), this is only checked in a minority of cases by peer-reviewers (6). But even if 102 considered, looking only at the latest registry entry may lead to a wrong assessment, as changes to 103 the entry over the course of the study would remain 'hidden behind the latest entry'. One would 104 have to take a closer look at the history of changes, which some trial registries maintain, but which is 105 often not easily accessible. 106 Several analyses have already assessed the frequency of outcome discrepancies between registries and publications. They widely agree that this problem is very common, with a median estimated 107 108 prevalence of 31% of clinical trials affected by primary outcome changes (interquartile range across 109 analyses: 17-45 %) (7). However, most studies published to date did not report which registry entry 110 version they used (8–16), assessed discrepancies between the publication and the latest available 111 registry entry (17–19), or the latest registry entry before trial completion (20); some also used the first available entry or first entry during the active phase (21,22). Some studies determined the 112 timepoint of primary outcome registration and the timepoints of changes using registry histories 113 (23–28). Only two studies assessed changes over the course of the registry history, using small 114 115 samples and a simple terminology (29,30). No study quantified the number of changes missed by 116 considering only the latest registry entries.

117	In this study, we aimed to assess [1] how often changes to primary outcomes of clinical trials are
118	reported in clinical trial registries across all available registry entry versions ('within-registry
119	discrepancies'), [2] how often there are discrepancies between the latest registry entry and the
120	results publication ('registry-publication discrepancies'), [3] how many changes are 'hidden' behind
121	the latest registry entry, i.e., are 'within-registry', but do not show up as 'registry-publication
122	discrepancies' and are therefore easily missed in review, [4] how often both types of outcome
123	changes are transparently reported in the results publications, and [5] which trial characteristics are
124	associated with these reporting deficits.
125	
126	Methods
127	
128	Data sources and sample
129	We based our analyses on two published datasets (from the IntoValue projects, 31,32) containing all
130	interventional studies completed at German University Medical Centres between 2009 and 2017. The
131	trials had been registered in either ClinicalTrials.gov or the Deutsches Register Klinischer Studien
132	(DRKS), which is the WHO primary trial registry for Germany. Both registries have an accessible
133	history of changes. Our datasets also include links to corresponding results publications, which had
134	been manually identified. We retrieved a combined dataset for both projects from a GitHub
135	repository ( <u>https://github.com/maia-sh/intovalue-data</u> ), accessed on 24 January 2022).
136	
137	Eligibility criteria
138	We included any study that: 1) has a registry entry in either the ClinicalTrials.gov or the DRKS
139	database, 2) was completed between 2009 and 2017 according to the trial status described as
140	'Completed', 'Unknown status', 'Terminated', or 'Suspended' (ClinicalTrials.gov), or 'Recruiting
141	complete, follow-up complete', 'Recruiting stopped after recruiting started', or 'Recruiting suspended
142	on temporary hold' (DRKS), 3) reported in the registry that a German University Medical Centre was
143	involved (i.e., mentioned as responsible party, lead/primary sponsor, principal investigator, study
144	chair, study director, facility, collaborator, or recruitment location; for definitions see 31,32), 4) has
145	published results, i.e., a full-text publication of the trial results was found by the search methods
146	described in the IntoValue protocols (31,32), 5) is registered as a randomised trial.
147	

148 Data extraction and processing

We used a stepwise approach of automatic data extraction and processing followed by reviewer
assessment of identified outcome discrepancies, first comparing outcomes within the registry and
second comparing registry entries with publications.

152 Automatic data extraction and processing. We obtained trial identifiers (NCT or DRKS number) and

basic information about the trials and accompanying publications from the IntoValue dataset (31,32).

154 We then downloaded all historical registry entries of these trials, using the cthist R package (33), on

- 155 24 January 2022 (DRKS) and 12 April 2022 (ClinicalTrials.gov). We extracted data from the fields listed
- 156 in the codebook (https://osf.io/syux2). For our classification of within-registry discrepancies, we
- 157 extracted primary and secondary outcomes at four key registration milestones: [1] the first entry
- after study start (inclusion of the first patient), [2] the latest entry before the end of active status
- 159 (determined e.g. by 'completed' status in the registry), [3] the latest entry before publication of the
- 160 results in a journal, and [4] latest available entry.
- 161 We classified trials into medical fields based on their journal's category from the SCImago Journal &
- 162 Country Rank database (34), which is based on the Scopus medical field classification. The journals'
- 163 categories were divided into 17 higher-order categories based on consensus (MRH, MH, LGH).
- 164 Assessment of within-registry outcome discrepancies. Two reviewers (MRH, MH) conducted the
- assessment of within-registry discrepancies in duplicate and resolved conflicts through discussion.
- 166 Reviewers assessed changes to the primary outcomes between the four key trial milestones within
- the registry (Figure 1), using a classification system based on prior assessments of outcome switching
- 168 (23,35) and descriptions of the specification of primary outcome measures (36) (Table 1).
- 169 Assessment of registry-publication outcome discrepancies. For feasibility, we drew a random sample
- 170 of 300 publications, from which three reviewers (MRH, MH, SY) extracted primary outcomes. Some
- 171 of these publications, however, turned out to not be the primary results publications of their
- 172 respective trials. If the reviewers could not find the correct publication, they excluded the
- 173 publication, reducing the final sample size to 292. We considered outcomes primary if they were
- 174 explicitly named as such using a list of keywords ('primary' / 'main' / 'outcome' / 'endpoint' / 'end
- point'). Otherwise, we used the outcome used for sample size calculation. In all other cases, we used
- 176 the first reported outcome in the abstract and results section (with priority given to the abstract). For
- 177 each entry, reviewers compared the extracted primary outcome(s) with the latest available registry
- 178 entry using the developed rating system (Table 1). Reviewers also recorded whether there were any
- 179 mentions of outcome changes in the assessed publications. Conflicts were resolved through
- 180 discussion between raters.
- 181 Inter-rater agreement. The overall inter-rater agreement over all timepoints and items (measured by
- 182 Cohen's kappa) during screening was  $\kappa = 0.81$  for the within-registry ratings and  $\kappa = 0.46$  during the
- 183 registry-publication ratings. Disagreement resulted partly from cases without clear reporting of
  - 6

184	primary outcomes in publications (if only explicitly mentioned outcomes were used for the registry-
185	publication ratings, inter-rater agreement was $\kappa$ = 0.51). In a post-hoc sensitivity analysis we
186	restricted our analysis to primary outcomes explicitly named as such in the publications or used for
187	sample size calculation.
188	
189	Statistical analyses and reporting
190	We report descriptive statistics for the rates of different types of outcome discrepancies within the
191	registry entries (between key trial milestones), and between the latest registry entries and results
192	publications. For proportions within the random sample of 292 trials with manual assessment of
193	publications, we report 95% confidence intervals. For the analysis of determinants of within-registry
194	outcome discrepancies or registry-publication outcome discrepancies, we used logistic regressions,
195	with either any within-registry outcome discrepancy, or any registry-publication outcome
196	discrepancy, as response variables, and a set of 9 candidate predictors (study phase, sponsor,
197	publication year, registration year, medical field, registry, multicenter trial, enrollment, intervention).
198	These variables were prespecified before the start of regression analyses (details in Supplementary
199	Table 1).
200	Software. We used the R package cthist (33) to download clinical trial registration histories, Numbat
201	Systematic Review Manager (37) for data extraction, and R (38) for data processing and statistical
202	analyses.
203	<i>Reporting.</i> We used the STROBE guideline (39) to structure our manuscript.
204	
205	Results
206	
207	We included 1746 clinical trials completed at German University Medical Centres between 2009 and
208	2017 (Table 2; Figure 2). Median registered sample size of these trials was 100, their median
209	registration year 2011 and median publication year 2015. The largest fields represented by these
210	trials were general medicine (29%) and internal medicine (17%). Industry was the lead sponsor for
211	26% of trials.
242	
212	
213	Prevalence of outcome discrepancies
214	Primary outcome discrepancies within trial registries.

- Of 1746 trials, 393 (23%) had an outcome discrepancy reported within the registry (Table 3; Figure 3),
- 216 142 trials (8%) had major discrepancies, i.e., a primary outcome was newly added, dropped, or
- 217 changed to or from a secondary outcome. Of these major discrepancies, 66 (4%) happened during
- 218 the active phase of the trial, i.e., after first patient inclusion and before the trial status was set to
- 219 'completed', another 49 (3%) between completion and publication, and 36 (2%) after publication.
- 220 Minor discrepancies were seen in 318 (18%) trials.
- 221 Primary outcome discrepancies between registry entries and publications.
- 222 Out of 292 randomly selected trials among the 1746 trials, 120 (41%; 95% CI [35%, 47%]) had a
- discrepancy between the latest registry entry and the publication, of which 54 (18%; 95% CI [14%,
- 224 23%]) were major and 75 (26%; 95% CI [21%, 31%]) were minor discrepancies.
- 225

# 226 Hidden changes of primary outcomes

Among the 292 trials, 161 (55%: 95% CI [49%, 61%]) had an outcome discrepancy at any stage (Figure

4; Figure S1 and S2). There were discrepancies only between the latest registry entry and the

- 229 publication in 95 trials (33%; 95% CI [27%, 38%]), with 42 being major (14%) and 61 being minor
- 230 (21%); discrepancies only within the registry histories in 41 trials (14%; 95% CI [10%, 19%]) with 13
- 231 being major (4%) and 35 being minor (12%); and 25 trials (9%; 95% CI [6%, 12%]), 12 major (4%) and
- 14 minor (5%), had discrepancies both between the latest registry entry and the publication and also
- 233 within the registry.

234

# 235 **Reporting of changes in the publications**

Only two of the 161 trials with any change to the outcomes reported this change in the publication
(1%, 95% CI [0%, 4%]). One of the trials, which exhibited a major change both within the registry
(between completion and publication) and between the latest registry entry and publication, stated

- that some of the primary outcomes were going to be reported in a separate manuscript (40). The
- other publication, which had a major change between the latest entry and the publication, stated
- that the changed outcome was the 'more sensitive and direct measurement' (41).

242

# 243 Trial characteristics associated with outcome changes (within-registry and registry-publication)

- 244 Within-registry outcome changes were more likely in industry-sponsored trials (47% Industry vs 14%
- 245 Non-Industry, OR 0.29, 95% CI [0.21, 0.41], p < 0.001; Supplementary Table 1), trials registered on
- ClinicalTrials.gov (27% ClinicalTrials.gov vs 5% DRKS, OR 0.41, 95%CI [0.23, 0.70], p = 0.002), and trials 246
- 247 that were registered earlier (per registration year; OR 0.74, 95% CI [0.69, 0.80], p < 0.001). No
- 248 statistically significant association with any other trial characteristic was found.
- 249 For registry-publication outcome discrepancies, we identified no statistically significant association
- 250 with any candidate predictor (Supplementary Table 2).
- 251 We detected no statistically significant association between within-registry outcome discrepancies
- 252 and registry-publication outcome discrepancies (Supplementary Table 3).
- 253 Results were similar in the sensitivity analysis (Supplementary Table 4).
- 254
- 255

### Discussion

256

257 Our assessment of all 1746 published clinical trials conducted at German university medical centres 258 that were completed between 2009 and 2017 shows that changes to primary outcomes are very 259 common. About one in four trials (23%) has discrepancies within the registry after study start; a major discrepancy occurs within one in twelve trials (8%). Of the 292 assessed publications, 41% have 260 261 discrepancies between latest registry entry and the outcomes presented to readers, and 14% of the trials had changes 'hidden' within the registry, with no visible discrepancy between the latest entry 262 263 and the publication. These 'hidden' discrepancies were major in 4% of trials. An inspection of only the latest registry entry alongside the publication, without assessment of the entire registration 264 265 history, would miss a primary outcome change, which is often major, in one in seven trials. 266 We used a comparatively large sample of German clinical trials registered between 2009 and 2017, 267 with a validated set of corresponding results publications for registry entries, determined by an 268 extensive manual screening process (31,32). Our methodology allowed us to detect changes to 269 registered primary outcomes that might have gone unnoticed by other studies, by retrieving all historical versions for trials, and detecting changes using a streamlined workflow. This is different 270 from previous studies, which instead used manual searches (29,30). Many trials in our sample had 271 changes to the registry after study completion (9%) or after publication of the first results paper (8%). 272 The changes were almost never reported in the paper. We revealed potential indicators for these 273 274 practices, with trials that were registered earlier, trials registered on ClinicalTrials.gov, and industry-275 sponsored trials having a higher likelihood of within-registry outcome discrepancies.

276 Assessments of outcome changes that rely on a single version of registry entries might 277 underestimate the true prevalence of discrepancies. The ICMJE policy states that any changes to the 278 registration should be explained by authors in the publication (4). Both the observed lack of reporting 279 on outcome discrepancies in results publications, as well as survey results among manuscript 280 reviewers (6), indicate that reviewers check the registry entry of a clinical trial only in the minority of 281 cases. While registries make change histories available and offer tools to compare different 282 registration versions, and journal editors and reviewers in many cases use these tools to check the 283 registration histories, the low number of reporting of discrepancies in primary outcomes suggests 284 that this is not properly enforced. To counteract, journals could implement editorial policies that do 285 require editors, peer reviewers, or other personnel to assess the historical versions of submitted 286 clinical trials. Clinical trial registries, on the other hand, could help by implementing solutions to 287 identify and mark trials with major discrepancies in their outcomes.

288 Still, some trials change their outcomes at two or even three different timepoints over the course of 289 the trial. Interestingly, we found not only cases in which primary outcomes gained more detail, but 290 also cases in which primary outcomes were described with less detail than before. Overall, we found 291 55% of trials to have some form of outcome change over the course of the study. This is somewhat 292 higher compared to other studies, which exhibit a large range for the frequency, with a median of 293 31% (Interquartile Range: 17-45 % (7)). This might be due to different methodology, samples, 294 timepoints, or definition of outcome discrepancies. A common reference used in other assessments 295 of outcome discrepancies is the study by Chan et al. (35) that used a more narrow definition of 296 outcome changes (roughly corresponding to our 'major' category). We used a relatively liberal 297 definition of primary outcome changes, defining added or omitted specificity as minor discrepancies. 298 This study has several limitations. First, we rely on the reporting quality of published studies. In 48 299 out of 292 publications, the primary outcome was not explicitly mentioned in the publication, so we 300 had to take the outcome used for sample size calculation or the first reported outcome instead. A sensitivity analysis excluding these 48 studies supported our main analysis. Second, the 301 302 categorisation of outcome changes is somewhat subjective, and while the agreement was very high 303 for the within-registry changes ( $\kappa = 0.81$ ), it was moderate ( $\kappa = 0.46$ ) for the registration-publication 304 ratings due to the added complexity of identifying the correct outcome as 'primary'. However, both 305 conflicting primary outcome definitions and conflicting ratings were resolved in discussions between 306 the reviewers, and excluding unclear situations in the abovementioned sensitivity analysis did not change the main findings. Third, although we used high quality underlying data reflecting German 307 308 clinical research output, we only assess a single geographic area, partly reflecting EU/German 309 registration policies. Finally, we only looked at changes between registry entries but did not check

it is made available		

310	how many outcome measures that show no change remain underspecified (e.g., no information on		
311	the type of measurement, timing, or method of aggregation).		
312	Overall, our analysis did not only reveal these research findings but also demonstrated the feasibility		
313	of an efficient workflow (33) that can be used for future projects and overcome previously described		
314	challenges to incorporate historical registration data (42).		
315			
316	Conclusion		
317			
318	Primary outcome discrepancies are very common in clinical research. Such discrepancies are often		
319	hidden in the trial registries and almost never reported in publications. The problem seems to be		
320	ubiquitous, but may be more common in older trials, trials registered in ClinicalTrials.gov, and		
321	industry-sponsored trials. Even though trial registries can be an important tool to detect outcome		
322	discrepancies, review procedures employed by journals seem to rarely make use of them. Our		
323	approach provides a feasible approach to further investigate this issue. Overall, it is not sufficient to		
324	only assess the publication and latest registry entry – a careful assessment of the full research		
325	conduct from conception to publication is needed to ensure trustworthy evidence for clinical		
326	decisions.		

#### 327 References

- Zarin DA, Keselman A. Registering a clinical trial in ClinicalTrials.gov. Chest. 2007 328 1. 329 Mar;131(3):909–12.
- 2. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 330 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. 331 332 BMJ. 2010 Mar 23;340(mar23 1):c869–c869.
- 333 3. Simmons JP, Nelson LD, Simonsohn U. False-Positive Psychology: Undisclosed Flexibility in Data Collection and Analysis Allows Presenting Anything as Significant. Psychol Sci. 2011 334 Nov;22(11):1359-66. 335
- 336 4. ICMJE. International Committee of Medical Journal Editors Recommendations for the Conduct, 337 Reporting, Editing, and Publication of Scholarly Work in Medical Journals [Internet]. [cited 2021 Oct 18]. Available from: http://www.icmje.org/icmje-recommendations.pdf 338
- WMA. World Medical Association: Declaration of Helsinki Ethical Principles for Medical 339 5. 340 Research involving Human Subjects [Internet]. 2018. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-341 medical-research-involving-human-subjects/ 342
- 6. Mathieu S, Chan AW, Ravaud P. Use of Trial Register Information during the Peer Review 343 Process. Smalheiser NR, editor. PLoS ONE. 2013 Apr 10;8(4):e59910. 344
- 345 7. Jones CW, Keil LG, Holland WC, Caughey MC, Platts-Mills TF. Comparison of registered and 346 published outcomes in randomized controlled trials: a systematic review. BMC Med. 2015 347 Dec;13(1):282.
- Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial Publication after Registration in 348 8. 349 ClinicalTrials.Gov: A Cross-Sectional Analysis. Sim I, editor. PLoS Med. 2009 Sep 350 8;6(9):e1000144.
- 351 9. Smith SM, Wang AT, Pereira A, Chang DR, McKeown A, Greene K, et al. Discrepancies between 352 registered and published primary outcome specifications in analgesic trials: ACTTION systematic review and recommendations. Pain. 2013 Dec;154(12):2769-74. 353
- 354 10. Bourgeois FT. Outcome Reporting Among Drug Trials Registered in Clinical Trials.gov. Ann Intern 355 Med. 2010 Aug 3;153(3):158.
- 356 11. Chahal J, Tomescu SS, Ravi B, Bach BR, Ogilvie-Harris D, Mohamed NN, et al. Publication of 357 Sports Medicine–Related Randomized Controlled Trials Registered in ClinicalTrials.gov. Am J 358 Sports Med. 2012 Sep;40(9):1970-7.
- 359 12. Gandhi R, Jan M, Smith HN, Mahomed NN, Bhandari M. Comparison of published orthopaedic trauma trials following registration in Clinicaltrials.gov. BMC Musculoskelet Disord. 2011 360 361 Dec;12(1):278.
- 13. Killeen S, Sourallous P, Hunter IA, Hartley JE, Grady HLO. Registration Rates, Adequacy of 362 363 Registration, and a Comparison of Registered and Published Primary Outcomes in Randomized 364 Controlled Trials Published in Surgery Journals. Ann Surg. 2014 Jan;259(1):193-6.

- Li XQ, Yang GL, Tao KM, Zhang HQ, Zhou QH, Ling CQ. Comparison of registered and published
   primary outcomes in randomized controlled trials of gastroenterology and hepatology. Scand J
   Gastroenterol. 2013 Dec;48(12):1474–83.
- 36815.Rosenthal R, Dwan K. Comparison of Randomized Controlled Trial Registry Entries and Content369of Reports in Surgery Journals. Ann Surg. 2013 Jun;257(6):1007–15.
- Wildt S, Krag A, Gluud L. Characteristics of randomised trials on diseases in the digestive system
   registered in ClinicalTrials.gov: a retrospective analysis. BMJ Open. 2011 Oct 27;1(2):e000309–
   e000309.
- Becker JE, Krumholz HM, Ben-Josef G, Ross JS. Reporting of results in ClinicalTrials.gov and high impact journals. JAMA. 2014 Mar 12;311(10):1063–5.
- Hartung DM, Zarin DA, Guise JM, McDonagh M, Paynter R, Helfand M. Reporting Discrepancies
   Between the ClinicalTrials.gov Results Database and Peer-Reviewed Publications. Ann Intern
   Med. 2014 Apr 1;160(7):477.
- Ewart R, Lausen H, Millian N. Undisclosed Changes in Outcomes in Randomized Controlled
   Trials: An Observational Study. Ann Fam Med. 2009 Nov 1;7(6):542–6.
- Nankervis H, Baibergenova A, Williams HC, Thomas KS. Prospective Registration and Outcome Reporting Bias in Randomized Controlled Trials of Eczema Treatments: A Systematic Review. J
   Invest Dermatol. 2012 Dec;132(12):2727–34.
- Jones CW, Misemer BS, Platts-Mills TF, Ahn R, Woodbridge A, Abraham A, et al. Primary
  outcome switching among drug trials with and without principal investigator financial ties to
  industry: a cross-sectional study. BMJ Open. 2018 Feb 8;8(2):e019831.
- Jones CW, Platts-Mills TF. Quality of Registration for Clinical Trials Published in Emergency
   Medicine Journals. Ann Emerg Med. 2012 Oct;60(4):458-464.e1.
- Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of Registered and Published
   Primary Outcomes in Randomized Controlled Trials. JAMA. 2009 Sep 2;302(9):977.
- Hannink G, Gooszen HG, Rovers MM. Comparison of Registered and Published Primary
   Outcomes in Randomized Clinical Trials of Surgical Interventions. Ann Surg. 2013
   May;257(5):818–23.
- Milette K, Roseman M, Thombs BD. Transparency of outcome reporting and trial registration of
   randomized controlled trials in top psychosomatic and behavioral health journals: A systematic
   review. J Psychosom Res. 2011 Mar;70(3):205–17.
- Walker KF, Stevenson G, Thornton JG. Discrepancies between registration and publication of
   randomised controlled trials: an observational study. JRSM Open. 2014 May
   1;5(5):204253331351768.
- Pinto RZ, Elkins MR, Moseley AM, Sherrington C, Herbert RD, Maher CG, et al. Many
   Randomized Trials of Physical Therapy Interventions Are Not Adequately Registered: A Survey
   of 200 Published Trials. Phys Ther. 2013 Mar 1;93(3):299–309.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.20.23286182; this version posted February 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 402 28. Anand V, Scales DC, Parshuram CS, Kavanagh BP. Registration and design alterations of clinical 403 trials in critical care: a cross-sectional observational study. Intensive Care Med. 2014 404 May;40(5):700-22.
- 405 29. Huić M, Marušić M, Marušić A. Completeness and Changes in Registered Data and Reporting Bias of Randomized Controlled Trials in ICMJE Journals after Trial Registration Policy. Siegfried 406 407 N, editor. PLoS ONE. 2011 Sep 21;6(9):e25258.
- 408 30. Pranić S, Marušić A. Changes to registration elements and results in a cohort of Clinicaltrials.gov 409 trials were not reflected in published articles. J Clin Epidemiol. 2016 Feb;70:26–37.
- 410 31. Riedel N, Wieschowski S, Bruckner T, Holst MR, Kahrass H, Nury E, et al. Results dissemination from completed clinical trials conducted at German university medical centers remained 411 412 delayed and incomplete. The 2014 – 2017 cohort. J Clin Epidemiol. 2022 Apr;144:1–7.
- 413 32. Wieschowski S, Riedel N, Wollmann K, Kahrass H, Müller-Ohlraun S, Schürmann C, et al. Result dissemination from clinical trials conducted at German university medical centers was delayed 414 415 and incomplete. J Clin Epidemiol. 2019 Nov;115:37–45.
- 33. Carlisle BG. Analysis of clinical trial registry entry histories using the novel R package cthist. 416 417 Naudet F, editor. PLOS ONE. 2022 Jul 1;17(7):e0270909.
- 418 34. Scimago Journal & Country Rank [Internet]. 2022 [cited 2022 Oct 31]. Available from: 419 https://www.scimagojr.com/journalrank.php
- 420 35. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials: Comparison of Protocols to Published Articles. 421 422 JAMA. 2004 May 26;291(20):2457.
- 423 36. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov Results Database — Update 424 and Key Issues. N Engl J Med. 2011 Mar 3;364(9):852–60.
- 425 37. Carlisle BG. Numbat {S}ystematic {R}eview {M}anager [Internet]. Berlin: The Grey Literature; 426 2014. Available from: https://numbat.bgcarlisle.com
- 427 38. R Core Team. R: A language and environment for statistical computing. [Internet]. Vienna, 428 Austria: R Foundation for Statistical Computing; 2022. Available from: https://www.R-429 project.org/
- 430 Elm E von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening 39. 431 the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for 432 reporting observational studies. The Lancet. 2007 Oct 20;370(9596):1453-7.
- 433 40. Alberer M, Burchard G, Jelinek T, Reisinger E, Beran J, Meyer S, et al. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: A randomized, open-label, 434 multi-center study. Travel Med Infect Dis. 2014 Sep;12(5):485-93. 435
- 436 Wiegand A, Sommer A, Nieratschker V, Plewnia C. Improvement of cognitive control and 41. 437 stabilization of affect by prefrontal transcranial direct current stimulation (tDCS). Sci Rep. 2019 438 Dec;9(1):6797.

- 439 42. Al-Durra M, Nolan RP, Seto E, Cafazzo JA. Prospective registration and reporting of trial number
- 440 in randomised clinical trials: global cross sectional study of the adoption of ICMJE and
- 441 Declaration of Helsinki recommendations. BMJ. 2020 Apr 14;m982.

#### 443 **Figures**

### 444



445

446 Figure 1. Key trial timepoints analysed for outcome discrepancies in this study.

- 447 Any changes of primary outcomes between study start and last available entry (i.e., within-registry
- discrepancies; registry data were downloaded in January 2022 for DRKS and in April 2022 for 448
- 449 ClinicalTrials.gov) were considered and compared to the journal publication (i.e., registry-publication
- 450 discrepancies).



452 Figure 2. Study flowchart.

Trial Conduct	Post-Completion	Post-Publication
Major (Start vs Completion)	Major (Completion vs F	Pub.) Major (Pub. vs Latest)
Minor (Start vs Completion)	Minor (Completion vs I	Pub.) Minor (Pub. vs Latest)
No Changes (Start vs Completion)	No Changes (Completion	No Changes (Pub. vs Latest) on vs Pub.) No Information
No Information	No Information	

454 Figure 3. Percentage of trials showing primary outcome discrepancies within the registry history per

455 trial phase. 'No information' means that a trial did not have a registry entry at that time or did not

456 have any updates to the registry entry at that time.







٦

### 466 Tables

467

468 Table 1. Categorisation of outcome discrepancies. Multiple categories could be present between two

469 timepoints.

Major discrepancies		
New primary outcome	A new primary outcome was introduced in a registry entry. This also applied when (seemingly) composite outcomes or different timepoints were split into separate primary outcomes.	
Primary from secondary	The new primary outcome was listed as a secondary outcome in the earlier registry entry.	
Primary outcome omitted	A previously registered primary outcome was completely omitted in the later registry entry.	
Primary to secondary	A previously registered primary outcome was reported as a secondary outcome in the later registry entry or publication. This also applied when (seemingly) composite outcomes were split into separate outcomes and some were later listed as secondary outcomes.	
Minor discrepancies		
Type of measurement changed, metric or method of aggregation changed, timing of assessment changed	Significant parts changed, e g., timing from {24h} to {48h}.	
Type of measurement specified, metric or method of aggregation specified, timing of assessment specified	Specified for the first time or significant detail added, e.g., from {seizure rate} to {seizure rate as recorded by family members}.	
Type of measurement omitted, metric or method of aggregation omitted, timing of assessment omitted	Significant details of the registered primary outcomes were completely omitted or described with less specificity, , e.g., from {seizure rate as recorded by family members} to {seizure rate}.	
No discrepancies		
No relevant change	<ul> <li>We did not consider, for example:</li> <li>Correction of typos,</li> <li>description of statistical analyses (e.g., intention-to-treat vs per-protocol population, statistical tests used),</li> <li>description of handling of missing data,</li> <li>addition of redundant descriptions of known scales (e.g., RECIST criteria, Visual Analogue Scale), or</li> <li>redundant details pertaining to measurement (e.g., change from baseline).</li> </ul>	

#### 471 Table 2. Characteristics of included trials.

Characteristic		N (%)	
Registration Year		2011 (2009; 2013)	
(median; IQR)			
Publication Year		2015 (2013;2017)	
(median; IQR)			
Sample size		100 (50; 264)	
(median; IQR)			
Medical Field	General Medicine	506 (29.0%)	
	Internal Medicine	288 (16.5%)	
	Neuroscience	100 (5.7%)	
	Pharmacology, Toxicology and	98 (5.6%)	
	Pharmaceutics		
	Oncology	95 (5.4%)	
	Surgery	76 (4.4%)	
	Psychology and Psychiatry	75 (4.3%)	
	Family & Reproductive Medicine	31 (1.8%)	
	Dentistry	23 (1.3%)	
Nursing		18 (1.0%)	
	Other	395 (22.6%)	
Study Phase	None/not applicable	862 (49.4%)	
	Phase: 1	56 (3.2%)	
	Phase: 2	268 (15.3%)	
	Phase: 3	382 (21.9%)	
	Phase: 4	178 (10.2%)	
Sponsor	Industry	455 (26.1%)	
	Other	1291 (73.9%)	
Registry	ClinicalTrials.gov	1402 (80.3%)	
	DRKS	344 (19.7%)	
Multicenter Trial No		930 (53.3%)	
	Yes	815 (46.7%)	
Intervention Device		281 (16.1%)	
Drug or Biological		631 (36.1%)	
	Other or not provided	834 (47.8%)	
Total		1746 (100%)	

- 473 Table 3. Primary outcome discrepancies in 1746 trials published between 2009 to 2017. The table
- shows the changes of primary outcomes reported in the registries at different trial timepoints 474
- compared to previous registry entries and the discrepancies detected in results publications 475
- 476 compared to the latest registry entry.

	Within-registry discrepancies per trial timepoint (n=1746)			Registry- publication discrepancies (n=292; sample)	
	Any	recruitment	post- completion	post- publication	
Discrepancies <b>any</b>	393 (22.51%)	167 (9.56%)	159 (9.11%)	131 (7.50%)	120 (41.10%) [35.40%, 46.98%]
major	142 (8.13%)	66 (3.78%)	49 (2.81%)	36 (2.06%)	54 (18.49%) [14.21%, 23.43%]
minor	318 (18.21%)	117 (6.70%)	130 (7.45%)	110 (6.30%)	75 (25.68%) [20.77%, 31.10%]
- changes	149 (8.53%)	49 (2.81%)	61 (3.49%)	51 (2.92%)	45 (15.41%) [11.47%, 20.07%]
- addition/omission	233 (13.34%)	78 (4.47%)	91 (5.21%)	80 (4.58%)	32 (10.96%) [7.62%, 15.12%]
milestone does not exist	5 (0.29%)	332 (19.01%)	266 (15.23%)	945 (54.12%)	0 (0.00%) [0.00%, 0.00%]
none	1348 (77.21%)	1247 (71.42%)	1321 (75.66%)	670 (38.37%)	172 (58.90%) [53.02%, 64.60%]